In their pivotal study, Barel et al. compared IdyllaTM (NRAS-BRAF-EGFRS492R mutation assay—110 min per sample) with NGS and IHC for detection of BRAF and NRAS mutations in 36 patients with metastatic melanomas and found a global concordance between NGS and IdyllaTM assays of 97.2% (35/36 cases) [34]. The gene discussed is BRAF; the disease is metastatic melanoma.